Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy: Its Role in Clinical Practice
Open Access
- 1 November 2003
- journal article
- research article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 5 (6) , 414-420
- https://doi.org/10.1111/j.1524-6175.2003.02836.x
Abstract
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers are commonly prescribed for the management of hypertension. In addition, each of these drug classes has been shown to be effective in the treatment of congestive heart failure, proteinuric chronic kidney disease, and most recently the high‐cardiac‐risk profile patient. The individual success of each of these drug classes has fueled the theory that given together, the overall biologic effect of both would surpass that of either given alone. The foundation of this premise, although biologically plausible, has yet to be proven in a compelling enough fashion to support the everyday use of these two drug classes in combination. Additional clarifying studies are required to establish whether specific patient subsets exist that might benefit from such combination therapy.Keywords
This publication has 66 references indexed in Scilit:
- Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: insights into mechanismClinical Nephrology, 2003
- Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal diseaseJournal of Human Hypertension, 2003
- Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension11See Editorial by Noris and Remuzzi, p. 1545.Kidney International, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?Current Opinion in Nephrology and Hypertension, 2001
- Add-on angiotensin receptor blockade with maximized ACE inhibitionKidney International, 2001
- Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patientsKidney International, 2000
- Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failureJournal of the Renin-Angiotensin-Aldosterone System, 2000
- Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal diseaseNephrology Dialysis Transplantation, 1999
- Angiotensin II Receptor Blockade Combined to ACE-Inhibition Improves Left Ventricular Dilation and Exercise Ejection Fraction in Congestive Heart FailureJournal of the American College of Cardiology, 1998